Tanattida Kassels

Tanattida Kassels

Auto-generated profile, based on publicly available information

Tanattida Kassels

Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2025 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
PNPannathorn Nakaphan
Pannathorn Nakaphan
PPPatavee Pajareya
Patavee Pajareya
PJPriabprat Jansem
Priabprat Jansem
SPSomkiat Phutinart
Somkiat Phutinart
NCNattanicha Chaisrimaneepan
Nattanicha Chaisrimaneepan
NSNoppachai Siranart
Noppachai Siranart

1 October 2025 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
PPPatavee Pajareya
Patavee Pajareya
NSNoppachai Siranart
Noppachai Siranart
NTNithi Tokavanich
Nithi Tokavanich
PKPonthakorn Keawkanha
Ponthakorn Keawkanha
WSWalit Sowalertrat
Walit Sowalertrat
RCRonpichai Chokesuwattanaskul
Ronpichai Chokesuwattanaskul

24 March 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
NSNoppachai Siranart
Noppachai Siranart
YCYanisa Chumpangern
Yanisa Chumpangern
PPPatavee Pajareya
Patavee Pajareya
PNPannathorn Nakaphan
Pannathorn Nakaphan
TKTanattida Kassels
Tanattida Kassels
KTKittithat Tantitanawat
Kittithat Tantitanawat
INTRODUCTION: Non-variceal upper gastrointestinal bleeding (NVGIB) represents an urgent medical condition with high mortality. Standard endoscopic therapies (ST) still carry a high rebleeding rate. Novel modalities such as the over-the-scope clip (OTSC) and hemostatic powder (HP) could be promising alternatives, but their efficacy and cost-effectiveness remain to be explored. METHODS: A network meta-analysis and cost-effectiveness analyses were conducted to compare OTSC vs HP vs ST. Primary endpoints include 30-day rebleeding and 30-day further bleeding. Markov models with a 12-month time horizon were created across 3 different health care settings: the United States, Thailand with Boston Scientific products (TH-BOS), and Thailand with China-manufactured alternatives (TH-CHN). Incremental cost-effectiveness ratio (ICER) was evaluated at a willingness-to-pay of $100,000 per quality-adjusted life year for the US model and THB 150,000 per quality-adjusted life year for the TH-BOS and TH-CHN models. RESULTS: Ten randomized controlled trials with 1,120 patients with NVGIB were included in the network meta-analysis. Lowest 30-day rebleeding was seen in OTSC ( P -score: 0.996), followed by ST (0.296) and HP (0.208). Similarly, OTSC also achieved lowest 30-day further bleeding (0.906), followed by HP (0.570) and ST (0.024). In cost-effective analysis, the US model reported OTSC as a dominant approach compared with HP (ICER: −$314) and ST (−$3,112). In the TH model, OTSC still dominated ST (ICER: −THB 28,423 for TH-BOS and −22,858 for TH-CHN) and was more cost-effective than HP (THB 1,833 for TH-BOS and THB 2,026 for TH-CHN). DISCUSSION: OTSC was superior to HP and ST in efficacy and cost-effectiveness, favoring its use as a first-line endoscopic hemostasis intervention for NVGIB.